Innovation geographies are reshaping life sciences portfolios

The evolution of global innovation geographies is reshaping the life sciences landscape, making location a more critical strategic factor than ever. According to our Innovation Geographies 2024 report, life sciences leaders are navigating a changing landscape of where growth is and will happen, joining tech and other knowledge-intensive sectors in the hunt for prime space in markets teeming with talent and resources. The prize: to target a precise mix of locations that support cutting-edge research and efficient production with direct access to the right talent, infrastructure and opportunities for collaboration.

Where to locate has long been a strategic consideration for forward-thinking life sciences leaders. But with rapid advances in fields like genomics, drug development, and medical devices, it’s gotten a lot more complex than setting up shop in a hot market. For both biopharma and medtech organizations, finding the right markets and submarkets has become critical for driving research and accelerating time-to-market innovations.

To stay ahead of fast-moving research and production needs, today’s real estate decisions must be more agile and informed than ever.

As innovation hubs reshape life sciences real estate, biopharma and medtech organizations alike must double down on portfolio innovation. With support from an expert global real estate partner, life sciences leaders can approach game-changing portfolio decisions with confidence—whether it’s expanding into new markets or optimizing existing spaces in the changing geography of innovation.